MHRA orders Class 3 recall of Tropicamide 1% eye drops after expiry date error
Aspire Pharma Ltd is recalling specific batches of Tropicamide 1% Eye Drops, solution in single-dose containers, after the packs were found to carry an incorrect expiry date. The correct expiry date for the affected batches is 31/10/2026, not the date printed on the label. The action has been classified as a Class 3 Medicines Recall, indicating a defect that is unlikely to cause harm but still requires removal from the supply chain and rapid stock control across pharmacy and dispensing settings.
The affected product is Tropicamide 1% Eye Drops, solution in single-dose containers 20 x 0.5 mL, PL: 35533/0198, with active ingredient tropicamide. The batches named in the recall are E941A, E941B, and E941C. Their printed expiry date appears as 30/04/2027 with an asterisk indicating the printed date is incorrect. First distribution dates were listed as 29/10/2025 for E941A, 04/02/2026 for E941B, and 20/02/2026 for E941C.
Label accuracy matters when ophthalmic stock moves quickly through the supply chain
Tropicamide is used in eye care settings where inventory may turn over rapidly and where expiry dating determines whether a product can safely remain in circulation. An error on the pack does not automatically mean the medicine has lost quality on the day the defect is identified, but it does create a clear risk of misuse if stock is retained beyond its actual approved shelf life. In practical terms, an incorrect expiry date can lead to dispensers, pharmacies, or clinic staff relying on the wrong information during routine stock checks. For a single-dose ophthalmic product, that kind of documentation defect is enough to justify recall, because visual examination alone cannot replace validated shelf-life data.
Healthcare professionals are instructed to stop supplying the affected batches immediately. Remaining stock should be quarantined and returned to the supplier using the approved process. The recall notice is explicit: do not continue to dispense the named batches once they have been identified in stock. In a dispensing environment, that means all locally held units must be separated from usable inventory at once, especially in settings where ophthalmic medicines are prepacked and distributed across several treatment rooms or satellite sites.
Patients are advised to keep using the medicine unless directed otherwise
The patient-facing advice is more restrained than the supply-side action. No further action is required from patients who already have these batches. They are advised to continue using the eye drops and contact the prescriber to obtain a replacement prescription. The recall has been undertaken as a precaution at the pharmacy and wholesaler level, and no adverse incidents linked to this defect have been reported to date.
This split approach reflects the nature of the defect. A mislabeled expiry date is a quality and governance problem first, not an immediate clinical toxicity signal. If the product is still within the true approved shelf life, sudden interruption of therapy is unnecessary and could create avoidable inconvenience, especially for patients who need pharmacologic pupil dilation for examination or ongoing ophthalmic assessment. The safety logic is straightforward: remove uncertain stock from professional circulation, but do not abruptly stop a patient’s current treatment when the defect concerns labeling rather than a known contamination or composition failure.
Patients who develop adverse reactions, or who have questions about their medication, should seek medical attention. Suspected adverse reactions should also be reported through the MHRA Yellow Card scheme. Even when a recall is precautionary, post-market surveillance remains central to identifying whether a packaging defect coincides with any unrecognized clinical problem.
Recall instructions focus on pharmacy control and prescriber communication
The notice directs recipients of the Medicines Recall to share it with relevant contacts, and NHS regional teams are asked to forward it to community pharmacists and dispensing general practitioners. That distribution pathway is important because the affected product may sit in different parts of the medicines chain, from wholesaler to community pharmacy to dispensing practice. The recall only works if every node in that chain acts on the same stock-keeping instruction.
For clinicians, the operational implication is simple. Stock reconciliation should identify whether any of the affected batches remain on site, and those packs should be removed from active use immediately. Because the error concerns a printed expiry date, staff should not rely on the label alone if there is any uncertainty about inventory status. The correct response is to quarantine and return the stock, then replace it through ordinary supply channels.
For pharmacies and dispensing GP practices, this is also a reminder of how fragile medication safety can be when labeling and supply controls drift out of alignment. Ophthalmic medicines are often handled in fast-moving workflow settings, and single-dose packs increase the chance that an individual unit is separated from its original carton before use. Once that happens, a wrong expiry date becomes more than an administrative defect; it can distort the final check that determines whether a product is still fit for dispensing.
Product details and reporting contacts remain unchanged
The medicine details listed in the notice are specific: Tropicamide 1% Eye Drops, solution in single-dose containers 20 x 0.5 mL, PL: 35533/0198, active ingredient tropicamide, SNOMED code 45542111000001107, and GTIN 5060209733661. Aspire Pharma Ltd is the marketing authorisation holder. The recall reference is DMRC-41341621.
The notice also provides separate contact points for medical information and stock control enquiries, both routed through Aspire Pharma Ltd. Those details matter for pharmacists who need clarification on replacement supply, as well as for any clinician seeking confirmation about the affected batches or their handling within local inventory systems.
The central clinical message is narrow but concrete: this is a labeling defect affecting specific Tropicamide 1% Eye Drops batches, not a report of patient injury. The stock must be removed from supply, yet patients already in possession of the product are told to continue treatment while arranging a replacement prescription if needed. No adverse incidents have been reported so far, but the recall depends on strict separation of affected stock before any mislabeled pack reaches a patient or remains in circulation beyond its true expiry date.